Asset
BERSACAPAVIR
Arrowhead Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03365947 | phase1_2 | completed | 2018-03-27 | 2020-04-23 | Arrowhead Pharmaceuticals | Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) |
FDA applications (0)
This company has no applications containing this asset.